中华实验外科杂志
中華實驗外科雜誌
중화실험외과잡지
CHINESE JOURNAL OF EXPERIMENTAL SURGERY
2014年
8期
1802-1804
,共3页
乳腺癌%微小RNA-30a
乳腺癌%微小RNA-30a
유선암%미소RNA-30a
Breast cancer%MicroRNA-30a
目的 探讨微小RNA(miRNA,miR)-30a在乳腺癌组织中的表达及其临床意义.方法 搜集46例具有完整临床病理资料及5年以上随访资料的石蜡包埋乳腺癌组织及其配对癌旁组织的病例.抽提总RNA,采用实时荧光定量聚合酶链反应(FQ-PCR)技术检测miR-30a在乳腺癌及其癌旁组织中的表达水平,并分析其与临床病理特征和患者预后的关系.结果 36例癌组织中miR-30 mRNA的相对表达水平为4.22±6.37,显著低于配对癌旁组织中miR-30a的表达(12.36±23.77,P＜0.01).乳腺癌组织中的miR-30a表达水平下调与肿瘤大小、TNM分期、淋巴结转移、雌激素受体(ER)以及孕激素受体(PR)表达明显相关(P＜0.05).Kaplan-Meier生存分析表明,miR-30a高表达组平均生存时间为92个月[95％可信区间(CI):87 ～ 109],低表达组平均生存时间为70个月(95％ CI:57 ～ 83),两组差异有统计学意义(x2=8.092,P＜0.01).Cox回归分析表明miR-30a低表达是乳腺癌预后不良的独立指标[风险比(HR)=4.07,95％ CI:2.89～ 5.26,P＜0.05].结论 miR-30a在乳腺癌组织中表达下调,与乳腺癌患者预后不良相关.
目的 探討微小RNA(miRNA,miR)-30a在乳腺癌組織中的錶達及其臨床意義.方法 搜集46例具有完整臨床病理資料及5年以上隨訪資料的石蠟包埋乳腺癌組織及其配對癌徬組織的病例.抽提總RNA,採用實時熒光定量聚閤酶鏈反應(FQ-PCR)技術檢測miR-30a在乳腺癌及其癌徬組織中的錶達水平,併分析其與臨床病理特徵和患者預後的關繫.結果 36例癌組織中miR-30 mRNA的相對錶達水平為4.22±6.37,顯著低于配對癌徬組織中miR-30a的錶達(12.36±23.77,P＜0.01).乳腺癌組織中的miR-30a錶達水平下調與腫瘤大小、TNM分期、淋巴結轉移、雌激素受體(ER)以及孕激素受體(PR)錶達明顯相關(P＜0.05).Kaplan-Meier生存分析錶明,miR-30a高錶達組平均生存時間為92箇月[95％可信區間(CI):87 ～ 109],低錶達組平均生存時間為70箇月(95％ CI:57 ～ 83),兩組差異有統計學意義(x2=8.092,P＜0.01).Cox迴歸分析錶明miR-30a低錶達是乳腺癌預後不良的獨立指標[風險比(HR)=4.07,95％ CI:2.89～ 5.26,P＜0.05].結論 miR-30a在乳腺癌組織中錶達下調,與乳腺癌患者預後不良相關.
목적 탐토미소RNA(miRNA,miR)-30a재유선암조직중적표체급기림상의의.방법 수집46례구유완정림상병리자료급5년이상수방자료적석사포매유선암조직급기배대암방조직적병례.추제총RNA,채용실시형광정량취합매련반응(FQ-PCR)기술검측miR-30a재유선암급기암방조직중적표체수평,병분석기여림상병리특정화환자예후적관계.결과 36례암조직중miR-30 mRNA적상대표체수평위4.22±6.37,현저저우배대암방조직중miR-30a적표체(12.36±23.77,P＜0.01).유선암조직중적miR-30a표체수평하조여종류대소、TNM분기、림파결전이、자격소수체(ER)이급잉격소수체(PR)표체명현상관(P＜0.05).Kaplan-Meier생존분석표명,miR-30a고표체조평균생존시간위92개월[95％가신구간(CI):87 ～ 109],저표체조평균생존시간위70개월(95％ CI:57 ～ 83),량조차이유통계학의의(x2=8.092,P＜0.01).Cox회귀분석표명miR-30a저표체시유선암예후불량적독립지표[풍험비(HR)=4.07,95％ CI:2.89～ 5.26,P＜0.05].결론 miR-30a재유선암조직중표체하조,여유선암환자예후불량상관.
Objective To investigate the abnormal expression of microRNA (miR)-30a in breast cancer and the clinical significance.Methods Forty-six cases of formalin-fixed and paraffin-embedded samples from breast cancer patients during a 5-year follow-up period and detailed clinicopathological information were selected.Total RNA was isolated and the expression of miR-30a was quantified by real-time fluorescent quantitative polymerase chain reaction (FQ-PCR).The relationship between miR-30a and the clinicopathological factors and the prognosis were analyzed.Results The expression of miR-30a in breast carcinoma tissues (4.22 ± 6.37) was significantly decreased as compared with that in the adjacent normal tissues (12.36 ± 23.77,P ＜ 0.01).The low expression of miR-30a was associated with tumor size,TNM stage,lymph node metastases,and expression of estrogen receptor (ER) and progesterone receptor (PR) (P ＜ 0.05).The overall survival in miR-30a high expression group was 93 months [95％ confidence interval (CI):87-109 months],significant longer than miR-30a low expression group (70 months,95％ CI:57-83 months ;x2 =8.092,P ＜ 0.01).Cox regression analysis showed that miR-30a low expression was one of independent prognostic impacts [Hazard ratio (HR) =4.07,95％ CI:2.89-5.26,P ＜0.05] for breast cancer.Conclusion The expression of miR-30a was down-regulated and was associated with poor prognosis in breast cancer,miR-30a may serve as an anti-oncogene in the development of breast cancer.
